Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Radiol Case Rep ; 17(12): 4834-4837, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36238214

ABSTRACT

A 60-year-old woman taking anti-platelet drugs was referred to the hospital for the treatment of advanced renal cell carcinoma. CT revealed that the tumor had a diameter of 5 cm and hyper-vascularity. Percutaneous CT-guided cryoablation (CA) was indicated. Since preprocedural arterial embolization failed to provide sufficient embolic effects, sunitinib maleate was administered. It provided good tumor devascularization and volume reduction, which corresponded to downstage. Therefore, the administration contributed to successfully performing subsequent percutaneous CT-guided CA with no serious hemorrhagic complications. Sunitinib maleate may be an alternative to conventional treatments before CA for renal cell carcinoma.

2.
J Vasc Interv Radiol ; 31(1): 114-120, 2020 01.
Article in English | MEDLINE | ID: mdl-31784332

ABSTRACT

PURPOSE: To evaluate whether administration of lidocaine into the uterine artery for anesthesia immediately after uterine artery embolization (UAE) with trisacryl gelatin microspheres (TAGM) for leiomyoma is safe and effective. MATERIALS AND METHODS: In a single-institution retrospective study, 100 patients underwent UAE using TAGM with a pruned tree endpoint between June 2014 and April 2019. The first 50 patients (control group) underwent UAE without lidocaine; in the second 50 patients (study group), lidocaine was administered into the uterine artery immediately after UAE. Baseline characteristics and technical and periprocedural outcomes were compared. Visual analog scale (VAS) scores 0, 3, 6, 9, 12, and 18 hours after UAE were compared between the groups with repeated measures analysis of variance. Each multivariate-adjusted VAS score < 24 hours was compared with analysis of covariance. RESULTS: No significant differences were observed in baseline characteristics or technical and periprocedural outcomes, including the volume of morphine used (P = .415), between the groups. No significant differences were found in crude or multivariate-adjusted VAS scores at each time point < 24 hours. Only the multivariate-adjusted VAS score 3 hours after UAE was 0.7 lower in the study group (mean ± SE, 2.2 ± 0.3 vs 2.9 ± 0.3); however, no significant difference was noted (P = .070). No adverse events associated with lidocaine were detected. CONCLUSIONS: Intra-arterial lidocaine administration immediately after UAE with TAGM for leiomyoma was safe, but did not contribute to significant reductions in pain or volume of narcotic agent administered.


Subject(s)
Acrylic Resins/administration & dosage , Anesthetics, Local/administration & dosage , Gelatin/administration & dosage , Leiomyoma/therapy , Lidocaine/administration & dosage , Pain/prevention & control , Uterine Artery Embolization , Uterine Neoplasms/therapy , Acrylic Resins/adverse effects , Adult , Analgesia, Patient-Controlled , Analgesics, Opioid/administration & dosage , Anesthetics, Local/adverse effects , Drug Administration Schedule , Female , Gelatin/adverse effects , Humans , Japan , Leiomyoma/pathology , Lidocaine/adverse effects , Middle Aged , Morphine/administration & dosage , Pain/diagnosis , Pain/etiology , Pain Measurement , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Uterine Artery Embolization/adverse effects , Uterine Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...